# Halozyme Therapeutics Inc. (HALO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $110.19, market value $12.5 billion.

## Valuation
- **P/E (trailing): 32.4×** (5-yr avg 22.4×, 3-yr avg 19.3×). Halozyme Therapeutics Inc. trades at 32.4× trailing earnings, well above its own five-year average of 22.4×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 10.6×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 7.5×**. Each dollar of revenue is priced at 7.5×.
- **Price / book: 87.5×**. The shares trade at 87.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 23.7×**. Enterprise value is 23.7× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 6.4%** (5-yr avg 6.2%). Free cash flow equals 6.4% of the market value, in line with its five-year average of 6.2%. Above 5% is generally attractive.
- **Earnings yield: 3.1%**. The inverse of the P/E: 3.1% of the price is earned each year.

## Profitability
- **Operating margin: 35.9%**. 35.9% of revenue is left after running the business, an exceptional level.
- **Net margin: 22.7%**. 22.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 649.2%**. A 649.2% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 22.9%**. Return on all capital, debt included, is 22.9%: comfortably above what that capital costs.
- **Return on assets: 16.4%**. Each dollar of assets produces 16.4% of profit.

## Growth
- **Revenue growth (1 yr): 37.6%** (3-yr 28.4%/yr, 5-yr 39.2%/yr). Revenue grew 37.6% over the last year, against 39.2% a year compounded over five years.
- **EPS growth (1 yr): -25.4%** (3-yr 21.1%/yr, 5-yr 23.0%/yr). Earnings per share fell 25.4%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 39.9%/yr**. Free cash flow has compounded at 39.9% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 43.89**. Debt is 43.89 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 3.3×**. It would take 3.3 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Altman Z-score: 4.22**. A Z-score of 4.22 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Halozyme Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover Halozyme Therapeutics Inc.; the consensus is buy, with an average price target of $99.56 (-10% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 50.1%** (YTD 63.7%, 3-mo 54.0%). The shares are up 50.1% over twelve months including dividends.
- **From 52-week high: -0.9%** (80.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 72**. An RSI of 72 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.55** (volatility 37%). Beta of 0.55 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=HALO · Page: https://foliofundamentals.com/stocks/halo

Not investment advice.